8-KOther EventsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Corporate Update (Jan 17, 2014)

Filed January 17, 2014For Securities:JNJ

Summary

Johnson & Johnson (JNJ) announced on January 16, 2014, that it has received a binding offer from The Carlyle Group to acquire its Ortho-Clinical Diagnostics business. The initial offer is for $4.15 billion, which will be subject to adjustments for working capital and other customary closing conditions. This divestiture represents a significant strategic move for Johnson & Johnson, allowing the company to potentially focus more resources on its core pharmaceutical and medical device segments.

Key Highlights

  • 1Binding offer received from The Carlyle Group to acquire Ortho-Clinical Diagnostics business.
  • 2Proposed sale price of $4.15 billion, subject to customary adjustments.
  • 3The transaction is expected to close around mid-2014, pending regulatory approvals and other conditions.
  • 4Johnson & Johnson will consult with works councils and trade unions during the acceptance period, which ends March 31, 2014.
  • 5The company plans to discuss this contemplated transaction further during its upcoming quarterly earnings meeting on January 21, 2014.
  • 6This divestiture aligns with potential strategic refocusing efforts for Johnson & Johnson.

Frequently Asked Questions

Johnson & Johnson has received a binding offer from The Carlyle Group to purchase its Ortho-Clinical Diagnostics business for $4.15 billion. The final price will be subject to adjustments for working capital and other customary terms.

If the offer is accepted and all conditions are met, including antitrust clearances, the transaction is expected to close around the middle of 2014.

Johnson & Johnson has until March 31, 2014, to accept the offer, during which time they will consult with relevant works councils and trade unions. The company will also discuss the potential sale during its January 21, 2014, earnings call.

While not explicitly stated, the sale of Ortho-Clinical Diagnostics suggests a potential strategic shift for Johnson & Johnson to concentrate on its core businesses in pharmaceuticals and medical devices. Further details may be provided during the upcoming earnings call.